-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FbRf+UgCuzkzQOgVwOI/lvMdcdTYdwHxTTz6Xv8fqC1/QiuH+eRdFEy6PEeFa60K ujv/yu9aAxjHksuAhL2q1Q== 0001144204-08-055041.txt : 20080929 0001144204-08-055041.hdr.sgml : 20080929 20080929153519 ACCESSION NUMBER: 0001144204-08-055041 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080925 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080929 DATE AS OF CHANGE: 20080929 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRESSURE BIOSCIENCES INC CENTRAL INDEX KEY: 0000830656 STANDARD INDUSTRIAL CLASSIFICATION: MEASURING & CONTROLLING DEVICES, NEC [3829] IRS NUMBER: 042652826 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21615 FILM NUMBER: 081094189 BUSINESS ADDRESS: STREET 1: 321 MANLEY STREET CITY: WEST BRIDGEWATER STATE: MA ZIP: 02379 BUSINESS PHONE: 5085801818 MAIL ADDRESS: STREET 1: 321 MANLEY STREET CITY: WEST BRIDGEWATER STATE: MA ZIP: 02379 FORMER COMPANY: FORMER CONFORMED NAME: BOSTON BIOMEDICA INC DATE OF NAME CHANGE: 19960812 8-K 1 v127539_8k.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 25, 2008

PRESSURE BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS

  (State or Other Jurisdiction of Incorporation)
 
  0-21615
 
  04-2652826
  (Commission File Number)
 
   (IRS Employer Identification No.)
 
  14 Norfolk Avenue, South Easton, MA
 
02375
(Address of Principal Executive Offices)
 
   (Zip Code)
 
(508) 230-1828

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 
 
(e) 2005 Equity Incentive Plan Amendment
 
On September 25, 2008, the stockholders of Pressure BioSciences, Inc. (the “Company”) approved an amendment to the Company’s 2005 Equity Incentive Plan (“2005 Equity Incentive Plan”), which increased the number of shares of common stock available for issuance under that plan by 500,000 from 1,000,000 to 1,500,000 shares.
 
The description above is a summary of the terms of the amendment to the 2005 Equity Incentive Plan. This description does not purport to be complete and it is qualified in its entirety by reference to Amendment No. 1 to the 2005 Equity Incentive Plan, a copy of which is attached to this report as Exhibit 10.1 and is incorporated herein by reference.
 
Item 8.01
Other Events
 
In addition to approving the amendment to the 2005 Equity Incentive Plan, as described in Item 5.02(e) above, on September 25, 2008, the stockholders of the Corporation approved the re-election of Mr. Richard T. Schumacher as a Class III Director of the Company to hold office until the 2011 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
 
The stockholders also approved the proposal, for purposes of complying with Nasdaq Marketplace Rule 4350(i)(1)(D), authorizing the Company to issue, in connection with one or more capital raising transactions, up to 4,500,000 shares of common stock (including pursuant to preferred stock, options, warrants, convertible debt or other securities exercisable for or convertible into common stock), upon such terms as the Board of Directors of the Company shall deem to be in the best interests of the Company, for an aggregate consideration of not more than $18,000,000 in cash and at a price not less than 80% of the market price of the Company’s common stock at the time of issuance, such issuances of common stock or other securities exercisable for or convertible into common stock to occur, if at all, in the three month period commencing with the date of the stockholder approval.
 
Item 9.01
Financial Statements and Exhibits 
 
(d)     Exhibits      
 
 
 
 
-2-

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
Dated: September 29, 2008
PRESSURE BIOSCIENCES, INC.
 
 
 
 
 
 
 
By:  
/s/ Edward H. Myles
 
Edward H. Myles,
Senior Vice President of Finance and
Chief Financial Officer

 
 
-3-

 
 
EXHIBIT INDEX
 
 
Exhibit Number
Exhibit Description    
   
10.1   
Amendment No. 1 to the Pressure BioSciences, Inc. 2005 Equity Incentive Plan.

 
 

 
EX-10.1 2 v127539_ex10-1.htm
 
EXHIBIT 10.1
 
 AMENDMENT NO. 1
TO
PRESSURE BIOSCIENCES, INC.
2005 EQUITY INCENTIVE PLAN
 
The following amendment to the Pressure BioSciences, Inc. (the “Corporation”) 2005 Equity Incentive Plan (the “Plan”) was approved by the Board of Directors of the Corporation on July 11, 2008, subject to the approval of the stockholders of the Corporation:
 
1. Section 3, Paragraph (a) is amended and restated by deleting the first sentence of this paragraph and replacing it with the following:
 
“Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company (the “Common Stock”) that may be issued pursuant to the Plan is 1,500,000.” 
 
2. Except as amended hereby, the 2005 Equity Incentive Plan shall remain in full force and effect in accordance with its original terms.
 
Approved by the Board of Directors: July 11, 2008
 
Approved by Stockholders: September 25, 2008
 
 
 

 
-----END PRIVACY-ENHANCED MESSAGE-----